Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.

Britta HöchsmannFlore Sicre de FontbruneJong Wook LeeAlexander Dmitrievich KulaginPeter HillmenAmanda WilsonJing L MarantzHubert Schrezenmeier

Published in: European journal of haematology (2022)

Eculizumab treatment in a real-world setting improved outcomes, including substantial decreases in hemolysis, MAVE rates, TEs, and transfusions in PNH patients regardless of HDA.

Keyphrases

disease activity
rheumatoid arthritis
end stage renal disease
systemic lupus erythematosus
atrial fibrillation
obstructive sleep apnea
blood pressure
chronic kidney disease
newly diagnosed
rheumatoid arthritis patients
ejection fraction
sleep quality
peritoneal dialysis
prognostic factors
sleep apnea